Applications of molecular imaging.
Applications of molecular imaging.
复制标题
DOI：
10.1016/b978-0-12-385071-3.00009-5
复制
发表时间：
2010
影响因子：
--
通讯作者：
Ross, Brian D.
中科院分区：
文献类型：
--
作者：
Galban, Craig J.;Galban, Stefanie;Van Dort, Marcian E.;Luker, Gary D.;Bhojani, Mahaveer S.;Rehemtulla, Alnawaz;Ross, Brian D.
今天，分子成像技术在临床肿瘤学中发挥着核心作用。成像技术在早期癌症检测、治疗反应和新疗法开发中的应用正在稳步增长，并已对癌症的临床管理产生重大影响。在本章中，我们将概述三种不同的分子成像技术，用于了解疾病的生物标志物，药物开发，或监测治疗结果。它们是（1）光学成像（生物发光和荧光成像）（2）磁共振成像（MRI）和（3）核成像（例如，单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET））。我们将审查使用的生物过程（如细胞凋亡和蛋白激酶活性）的分子报告的高通量药物筛选和新的癌症治疗，扩散MRI作为早期治疗反应的生物标志物和PET和SPECT放射性配体在肿瘤学。
Today molecular imaging technologies play a central role in clinical oncology. The use of imaging techniques in early cancer detection, treatment response and new therapy development is steadily growing and has already significantly impacted clinical management of cancer. In this chapter we will overview three different molecular imaging technologies used for the understanding of disease biomarkers, drug development, or monitoring therapeutic outcome. They are (1) optical imaging (bioluminescence and fluorescence imaging) (2) magnetic resonance imaging (MRI), and (3) nuclear imaging (e.g, single photon emission computed tomography (SPECT) and positron emission tomography (PET)). We will review the use of molecular reporters of biological processes (e.g. apoptosis and protein kinase activity) for high throughput drug screening and new cancer therapies, diffusion MRI as a biomarker for early treatment response and PET and SPECT radioligands in oncology.